Correction: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (Journal of the American College of Cardiology (2019) 74(10) (e177–e232), (S073510971933877X), (10.1016/j.jacc.2019.03.010));2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Journal of the American College of Cardiology

Volumn 74, Issue 10, 2019, Pages e177-e232

  Arnett, Donna K ^a   Blumenthal, Roger S ^a   Albert, Michelle A ^a   Buroker, Andrew B ^a   Goldberger, Zachary D ^a   Hahn, Ellen J ^a   Himmelfarb, Cheryl Dennison ^a   Khera, Amit ^a   Lloyd Jones, Donald ^a   McEvoy, J William ^a   Michos, Erin D ^a   Miedema, Michael D ^a   Muñoz, Daniel ^a   Smith, Sidney C ^a   Virani, Salim S ^a   Williams, Kim A ^a   Yeboah, Joseph ^a   Ziaeian, Boback ^a  

^a NONE

Author keywords

ACC AHA Clinical Practice Guidelines; antihypertensive agents; aspirin; atherosclerosis; atherosclerotic cardiovascular disease; atrial fibrillation; behavior modification; behavior therapy; blood cholesterol; blood pressure; body mass; cardiovascular; cardiovascular disease; cardiovascular team based care; cholesterol; chronic kidney disease; coronary artery calcium score; coronary disease; coronary heart disease; cost; diabetes mellitus; diet; dietary fats; dietary patterns; dietary sodium; dyslipidemia; e cigarettes; exercise; guidelines; health services accessibility; healthcare disparities; heart failure; hypertension; index; LDL cholesterol; lifestyle; lipids; measurement; myocardial infarction; nicotine; nonpharmacological treatment; nutrition; physical activity; prejudice; primary prevention; psychosocial deprivation; public health; quality indicators; quality measurement; risk assessment; risk factors; risk reduction; risk reduction discussion; risk treatment discussion; risk enhancing factors; secondhand smoke; sleep; smoking; smoking cessation; social determinants of health; socioeconomic factors; statin therapy; systems of care; tobacco; tobacco smoke pollution; treatment adherence; treatment outcomes; type 2 diabetes mellitus; waist circumference; weight loss

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG USE; EVIDENCE BASED MEDICINE; EXERCISE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT CARE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; RISK ASSESSMENT; TOBACCO USE; ADVISORY COMMITTEE;

ADVISORY COMMITTEES; CARDIOVASCULAR DISEASES; HUMANS; PRIMARY PREVENTION;

EID: 85071067121     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.07.011     Document Type: Erratum

References (467)

1. Weir, H.K., Anderson, R.N., Coleman King, S.M., et al. Heart disease and cancer deaths—trends and projections in the United States, 1969-2020. Prev Chronic Dis, 13, 2016, E157.
2. Johnson, N.B., Hayes, L.D., Brown, K., et al. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors—United States, 2005-2013. MMWR Suppl 63 (2014), 3–27.
3. Xu, J., Murphy, S.L., Kochanek, K.D., et al. Mortality in the United States, 2015. NCHS Data Brief, 2016, 1–8.
4. Greenland, P., Knoll, M.D., Stamler, J., et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290 (2003), 891–897.
5. Lloyd-Jones, D.M., Hong, Y., Labarthe, D., et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's Strategic Impact Goal through 2020 and beyond. Circulation 121 (2010), 586–613.
6. Turco, J.V., Inal-Veith, A., Fuster, V., Cardiovascular health promotion: an issue that can no longer wait. J Am Coll Cardiol 72 (2018), 908–913.
7. Younus, A., Aneni, E.C., Spatz, E.S., et al. A systematic review of the prevalence and outcomes of ideal cardiovascular health in US and non-US populations. Mayo Clin Proc 91 (2016), 649–670.
8. Whelton, P.K., Carey, R.M., Aronow, W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71 (2018), e127–e248.
9. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 Nov 10 [E-pub ahead of print].
10. Halperin, J.L., Levine, G.N., Al-Khatib, S.M., et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 67 (2016), 1572–1574.
11. Carter, B.L., Rogers, M., Daly, J., et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med 169 (2009), 1748–1755.
12. Chisholm-Burns, M.A., Kim Lee, J., Spivey, C.A., et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care 48 (2010), 923–933.
13. Fazel, M.T., Bagalagel, A., Lee, J.K., et al. Impact of diabetes care by pharmacists as part of health care team in ambulatory settings: a systematic review and meta-analysis. Ann Pharmacother 51 (2017), 890–907.
14. Mills, K.T., Obst, K.M., Shen, W., et al. Comparative effectiveness of implementation strategies for blood pressure control in hypertensive patients: a systematic review and meta-analysis. Ann Intern Med 168 (2018), 110–120.
15. Proia, K.K., Thota, A.B., Njie, G.J., et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med 47 (2014), 86–99.
16. Chen, Z., Ernst, M.E., Ardery, G., et al. Physician-pharmacist co-management and 24-hour blood pressure control. J Clin Hypertens (Greenwich) 15 (2013), 337–343.
17. Hirsch, J.D., Steers, N., Adler, D.S., et al. Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther 36 (2014), 1244–1254.
18. Hunt, J.S., Siemienczuk, J., Pape, G., et al. A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled hypertension. J Gen Intern Med 23 (2008), 1966–1972.
19. Isetts, B.J., Buffington, D.E., Carter, B.L., et al. Evaluation of pharmacists’ work in a physician-pharmacist collaborative model for the management of hypertension. Pharmacotherapy 36 (2016), 374–384.
20. McLean, D.L., McAlister, F.A., Johnson, J.A., et al. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med 168 (2008), 2355–2361.
21. Polgreen, L.A., Han, J., Carter, B.L., et al. Cost-effectiveness of a physician-pharmacist collaboration intervention to improve blood pressure control. Hypertension 66 (2015), 1145–1151.
22. Chen, E.H., Thom, D.H., Hessler, D.M., et al. Using the Teamlet Model to improve chronic care in an academic primary care practice. J Gen Intern Med 25:suppl 4 (2010), S610–S614.
23. Kravetz, J.D., Walsh, R.F., Team-based hypertension management to improve blood pressure control. J Prim Care Community Health 7 (2016), 272–275.
24. Wan, E.Y.F., Fung, C.S.C., Jiao27, F.F., et al. Five-year effectiveness of the Multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on diabetes-related complications and health service uses—a population-based and propensity-matched cohort study. Diabetes Care 41 (2018), 49–59.
25. Buhse, S., Mühlhauser, I., Heller, T., et al. Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial. BMJ Open, 5, 2015, e009116.
26. Cooper, L.A., Roter, D.L., Carson, K.A., et al. A randomized trial to improve patient-centered care and hypertension control in underserved primary care patients. J Gen Intern Med 26 (2011), 1297–1304.
27. Olomu, A., Hart-Davidson, W., Luo, Z., et al. Implementing shared decision making in federally qualified health centers, a quasi-experimental design study: the Office-Guidelines Applied to Practice (Office-GAP) program. BMC Health S24erv Res, 16, 2016, 334.
28. Parchman, M.L., Zeber, J.E., Palmer, R.F., Participatory decision making, patient activation, medication adherence, and intermediate clinical outcomes in type 2 diabetes: a STARNet study. Ann Fam Med 8 (2010), 410–417.
29. Havranek, E.P., Mujahid, M.S., Barr, D.A., et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation 132 (2015), 873–898.
30. Vilhelmsson, A., Östergren, P.-O., Reducing health inequalities with interventions targeting behavioral factors among individuals with low levels of education—a rapid review. PLoS ONE, 13, 2018, e0195774.
31. Schultz, W.M., Kelli, H.M., Lisko, J.C., et al. Socioeconomic status and cardiovascular outcomes: challenges and interventions. Circulation 137 (2018), 2166–2178.
32. Backholer, K., Peters, S.A.E., Bots, S.H., et al. Sex differences in the relationship between socioeconomic status and cardiovascular disease: a systematic review and meta-analysis. J Epidemiol Community Health 71 (2017), 550–557.
33. Beauchamp, A., Peeters, A., Tonkin, A., et al. Best practice for prevention and treatment of cardiovascular disease through an equity lens: a review. Eur J Cardiovasc Prev Rehabil 17 (2010), 599–606.
34. Khaing, W., Vallibhakara, S.A., Attia, J., et al. Effects of education and income on cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 24 (2017), 1032–1042.
35. Pollitt, R.A., Rose, K.M., Kaufman, J.S., Evaluating the evidence for models of life course socioeconomic factors and cardiovascular outcomes: a systematic review. BMC Public Health, 5, 2005, 7.
36. Schottenfeld, L., Petersen, D., Peikes, D., et al. Creating Patient-centered Team-based Primary Care. AHRQ Publication No. 16-0002-EF. 2016, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, Rockville, MD Available at: https://pcmh.ahrq.gov/page/creating-patient-centered-team-based-primary-care. (Accessed 3 January 2019)
37. Brush, J.E. Jr., Handberg, E.M., Biga, C., et al. 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers. J Am Coll Cardiol 65 (2015), 2118–2136.
38. Fentanes, E., Vande Hei, A.G., Holuby, R.S., et al. Treatment in a preventive cardiology clinic utilizing advanced practice providers effectively closes atherosclerotic cardiovascular disease risk-management gaps among a primary-prevention population compared with a propensity-matched primary-care cohort: a team-based care model and its impact on lipid and blood pressure management. Clin Cardiol 41 (2018), 817–824.
39. Billioux, A., Verlander, K., Anthony, S., et al. Standardized Screening for Health-Related Social Needs in Clinical Settings: The Accountable Health Communities Screening Tool. Available at: https://nam.edu/wp-content/uploads/2017/05/Standardized-Screening-for-Health-Related-Social-Needs-in-Clinical-Settings.pdf. (Accessed 5 January 2019)
40. Malambo, P., Kengne, A.P., De Villiers, A., et al. Built environment, selected risk factors and major cardiovascular disease outcomes: a systematic review. PLoS ONE, 11, 2016, e0166846.
41. DeFilippis, A.P., Young, R., McEvoy, J.W., et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J 38 (2017), 598–608.
42. Berkowitz, S.A., Hulberg, A.C., Standish, S., et al. Addressing unmet basic resource needs as part of chronic cardiometabolic disease management. JAMA Intern Med 177 (2017), 244–252.
43. Carnethon, M.R., Pu, J., Howard, G., et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation 136 (2017), e393–e423.
44. Rodriguez, C.J., Allison, M., Daviglus, M.L., et al. Status of cardiovascular disease and stroke in Hispanics/Latinos in the United States: a science advisory from the American Heart Association. Circulation 130 (2014), 593–625.
45. Volgman, A.S., Palaniappan, L.S., Aggarwal, N.T., et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation 138 (2018), e1–e34.
46. Magnani, J.W., Mujahid, M.S., Aronow, H.D., et al. Health literacy and cardiovascular disease: fundamental relevance to primary and secondary prevention: a scientific statement from the American Heart Association. Circulation 138 (2018), e48–e74.
47. Powell, T.M., de Lemos, J.A., Banks, K., et al. Body size misperception: a novel determinant in the obesity epidemic. Arch Intern Med 170 (2010), 1695–1697.
48. Padgett, J., Biro, F.M., Different shapes in different cultures: body dissatisfaction, overweight, and obesity in African-American and caucasian females. J Pediatr Adolesc Gynecol 16 (2003), 349–354.
49. U.S. Department of Health and Human Services. Healthy People 2020. Washington, DC: 2010. Available at: https://www.healthypeople.gov. Accessed January 3, 2019.
50. Bird, E.L., Ige, J.O., Pilkington, P., et al. Built and natural environment planning principles for promoting health: an umbrella review. BMC Public Health, 18, 2018, 930.
51. Kaiser, P., Diez Roux, A.V., Mujahid, M., et al. Neighborhood environments and incident hypertension in the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 183 (2016), 988–997.
52. Kumanyika, S.K., Gary, T.L., Lancaster, K.J., et al. Achieving healthy weight in African-American communities: research perspectives and priorities. Obes Res 13 (2005), 2037–2047.
53. Grandner, M.A., Addressing sleep disturbances: an opportunity to prevent cardiometabolic disease?. Int Rev Psychiatry 26 (2014), 155–176.
54. Knutson, K.L., Sociodemographic and cultural determinants of sleep deficiency: implications for cardiometabolic disease risk. Soc Sci Med 79 (2013), 7–15.
55. Ismail, K., Winkley, K., Rabe-Hesketh, S., Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 363 (2004), 1589–1597.
56. Alam, R., Sturt, J., Lall, R., et al. An updated meta-analysis to assess the effectiveness of psychological interventions delivered by psychological specialists and generalist clinicians on glycaemic control and on psychological status. Patient Educ Couns 75 (2009), 25–36.
57. Bolen, S.D., Chandar, A., Falck-Ytter, C., et al. Effectiveness and safety of patient activation interventions for adults with type 2 diabetes: systematic review, meta-analysis, and meta-regression. J Gen Intern Med 29 (2014), 1166–1176.
58. Gonzalez, J.S., Tanenbaum, M.L., Commissariat, P.V., Psychosocial factors in medication adherence and diabetes self-management: Implications for research and practice. Am Psychol 71 (2016), 539–551.
59. Javaheri, S., Redline, S., Insomnia and risk of cardiovascular disease. Chest 152 (2017), 435–444.
60. Samuel, L.J., Dennison Himmelfarb, C.R., Szklo, M., et al. Social engagement and chronic disease risk behaviors: the Multi-Ethnic Study of Atherosclerosis. Prev Med 71 (2015), 61–66.
61. Verbiest, M., Brakema, E., van der Kleij, R., et al. National guidelines for smoking cessation in primary care: a literature review and evidence analysis. NPJ Prim Care Respir Med, 27, 2017, 2.
62. Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2935–2959.
63. American College of Cardiology, American Heart Association. ASCVD Risk Estimator. Available at: https://tools.acc.org/ldl/ascvd_risk_estimator/index.html#!/calulate/estimator. (Accessed 21 September 2018)
64. Ference, B.A., Graham, I., Tokgozoglu, L., et al. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol 72 (2018), 1141–1156.
65. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 Nov 10 [E-pub ahead of print].
66. Patel, J., Al Rifai, M., Scheuner, M.T., et al. Basic vs more complex definitions of family history in the prediction of coronary heart disease: the Multi-Ethnic Study of Atherosclerosis. Mayo Clin Proc 93 (2018), 1213–1223.
67. del Rincón, I.D., Williams, K., Stern, M.P., et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44 (2001), 2737–2745.
68. Manzi, S., Meilahn, E.N., Rairie, J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 (1997), 408–415.
69. Wu, P., Haththotuwa, R., Kwok, C.S., et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes, 10, 2017, e003497.
70. Tanz, L.J., Stuart, J.J., Williams, P.L., et al. Preterm delivery and maternal cardiovascular disease in young and middle-aged adult women. Circulation 135 (2017), 578–589.
71. Wellons, M., Ouyang, P., Schreiner, P.J., et al. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause 19 (2012), 1081–1087.
72. Uddin, S.M.I., Mirbolouk, M., Dardari, Z., et al. Erectile dysfunction as an independent predictor of future cardiovascular events. Circulation 138 (2018), 540–542.
73. Triant, V.A., Perez, J., Regan, S., et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. Circulation 137 (2018), 2203–2214.
74. Volgman, A.S., Palaniappan, L.S., Aggarwal, N.T., et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation 138 (2018), e1–e34.
75. Ridker, P.M., Danielson, E., Fonseca, F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
76. DeFilippis, A.P., Young, R., Carrubba, C.J., et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 162 (2015), 266–275.
77. Mahabadi, A.A., Möhlenkamp, S., Lehmann, N., et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. J Am Coll Cardiol Img 10 (2017), 143–153.
78. Budoff, M.J., Young, R., Burke, G., et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J 39 (2018), 2401–2408.
79. McClelland, R.L., Jorgensen, N.W., Budoff, M., et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). J Am Coll Cardiol 66 (2015), 1643–1653.
80. Kavousi, M., Desai, C.S., Ayers, C., et al. Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis. JAMA 316 (2016), 2126–2134.
81. Carr, J.J., Jacobs, D.R. Jr., Terry, J.G., et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol 2 (2017), 391–399.
82. Mortensen, M.B., Fuster, V., Muntendam, P., et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol 68 (2016), 881–891.
83. Blaha, M.J., Cainzos-Achirica, M., Greenland, P., et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 133 (2016), 849–858.
84. Patel, J., Al Rifai, M., Blaha, M.J., et al. Coronary artery calcium improves risk assessment in adults with a family history of premature coronary heart disease: results from the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging, 8, 2015, e003186.
85. Pursnani, A., Massaro, J.M., D'Agostino, R.B. Sr., et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA 314 (2015), 134–141.
86. Valenti, V., Ó Hartaigh, B., Heo, R., et al. A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a prospective follow-up of 9,715 individuals. J Am Coll Cardiol Img 8 (2015), 900–909.
87. Yano, Y., O'Donnell, C.J., Kuller, L., et al. Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA Cardiol 2 (2017), 986–994.
88. Yeboah, J., Young, R., McClelland, R.L., et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol 67 (2016), 139–147.
89. Multi-Ethnic Study of Atherosclerosis. MESA 10-Year CHD Risk with Coronary Artery Calcification. Available at: https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx. (Accessed 21 September 2018)
90. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM). 10-Year ASCVD Risk Calculator with Coronary Artery Calcium. Available at: http://astrocharm.org/calculator-working. (Accessed 21 September 2018)
91. Gupta, A., Lau, E., Varshney, R., et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. J Am Coll Cardiol Img 10 (2017), 833–842.
92. Shah, R.V., Spahillari, A., Mwasongwe, S., et al. Subclinical atherosclerosis, statin eligibility, and outcomes in African American individuals: the Jackson Heart Study. JAMA Cardiol 2 (2017), 644–652.
93. Lloyd-Jones, D.M., Leip, E.P., Larson, M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113 (2006), 791–798.
94. Berry, J.D., Dyer, A., Cai, X., et al. Lifetime risks of cardiovascular disease. N Engl J Med 366 (2012), 321–329.
95. Wilkins, J.T., Ning, H., Berry, J., et al. Lifetime risk and years lived free of total cardiovascular disease. JAMA 308 (2012), 1795–1801.
96. Pencina, M.J., D'Agostino, R.B. Sr., Larson, M.G., et al. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 119 (2009), 3078–3084.
97. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
98. Whelton, P.K., Carey, R.M., Aronow, W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71 (2018), 2199–2269.
99. Pender, A., Lloyd-Jones, D.M., Stone, N.J., et al. Refining statin prescribing in lower-risk individuals: informing risk/benefit decisions. J Am Coll Cardiol 68 (2016), 1690–1697.
100. Andersson, C., Enserro, D., Larson, M.G., et al. Implications of the US cholesterol guidelines on eligibility for statin th4erapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc, 4, 2015, e001888.
101. Kavousi, M., Leening, M.J.G., Nanchen, D., et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 311 (2014), 1416–1423.
102. Pylypchuk, R., Wells, S., Kerr, A., et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 391 (2018), 1897–1907.
103. DeFilippis, A.P., Young, R., McEvoy, J.W., et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J 38 (2017), 598–608.
104. Emdin, C.A., Khera, A.V., Natarajan, P., et al. Evaluation of the pooled cohort equations for prediction of cardiovascular risk in a contemporary prospective cohort. Am J Cardiol 119 (2017), 881–885.
105. Rana, J.S., Tabada, G.H., Solomon, M.D., et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol 67 (2016), 2118–2130.
106. Cook, N.R., Ridker, P.M., Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med 174 (2014), 1964–1971.
107. Sussman, J.B., Wiitala, W.L., Zawistowski, M., et al. The veterans affairs cardiac risk score: recalibrating the atherosclerotic cardiovascular disease score for applied use. Med Care 55 (2017), 864–870.
108. Wolfson, J., Vock, D.M., Bandyopadhyay, S., et al. Use and customization of risk scores for predicting cardiovascular events using electronic health record data. J Am Heart Assoc, 6, 2017, e003670.
109. Muntner, P., Colantonio, L.D., Cushman, M., et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA 311 (2014), 1406–1415.
110. Colantonio, L.D., Richman, J.S., Carson, A.P., et al. Performance of the atherosclerotic cardiovascular disease pooled cohort risk equations by social deprivation status. J Am Heart Assoc, 6, 2017, e005676.
111. Crowson, C.S., Gabriel, S.E., Semb, A.G., et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford) 56 (2017), 1102–1110.
112. Dalton, J.E., Perzynski, A.T., Zidar, D.A., et al. Accuracy of cardiovascular risk prediction varies by neighborhood socioeconomic position: a retrospective cohort study. Ann Intern Med 167 (2017), 456–464.
113. Mora, S., Wenger, N.K., Cook, N.R., et al. Evaluation of the pooled cohort risk equations for cardiovascular risk prediction in a multiethnic cohort from the Women's Health Initiative. JAMA Intern Med 178 (2018), 1231–1240.
114. Yang, X., Li, J., Hu, D., et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (Prediction for ASCVD Risk in China). Circulation 134 (2016), 1430–1440.
115. Jung, K.J., Jang, Y., Oh, D.J., et al. The ACC/AHA 2013 pooled cohort equations compared to a Korean Risk Prediction Model for atherosclerotic cardiovascular disease. Atherosclerosis 242 (2015), 367–375.
116. D'Agostino, R.B. Sr., Vasan, R.S., Pencina, M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117 (2008), 743–753.
117. Ridker, P.M., Buring, J.E., Rifai, N., et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297 (2007), 611–619.
118. Ridker, P.M., Paynter, N.P., Rifai, N., et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118 (2008), 2243–2251 4p following 2251.
119. Catapano, A.L., Graham, I., De Backer, G., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37 (2016), 2999–3058.
120. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 100:suppl 2 (2014), ii1–ii67.
121. Anderson, T.J., Grégoire, J., Pearson, G.J., et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 32 (2016), 1263–1282.
122. Downs, J.R., O'Malley, P.G., Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med 163 (2015), 291–297.
123. Bibbins-Domingo, K., U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 164 (2016), 836–845.
124. U.S. Preventive Services Task Force Bibbins-Domingo, K., Grossman, D.C., et al. Statin use for the primary prevention of cardiovascular disease in adults: U.S. Preventive Services Task Force Re64commendation Statement. JAMA 316 (2016), 1997–2007.
125. Karmali, K.N., Goff, D.C. Jr., Ning, H., et al. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol 64 (2014), 959–968.
126. Mortensen, M.B., Nordestgaard, B.G., Afzal, S., et al. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. Eur Heart J 38 (2017), 586–594.
127. Mortensen, M.B., Afzal, S., Nordestgaard, B.G., et al. Primary prevention with statins: ACC/AHA risk-based approach versus trial-based approaches to guide statin therapy. J Am Coll Cardiol 66 (2015), 2699–2709.
128. Loprinzi, P.D., Addoh, O., Predictive validity of the American College of Cardiology/American Heart Association pooled cohort equations in predicting all-cause and cardiovascular disease-specific mortality in a national prospective cohort study of adults in the United States. Mayo Clin Proc 91 (2016), 763–769.
129. Yadlowsky, S., Hayward, R.A., Sussman, J.B., et al. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med 169 (2018), 20–29.
130. Nasir, K., Bittencourt, M.S., Blaha, M.J., et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 66 (2015), 1657–1668.
131. Miedema, M.D., Duprez, D.A., Misialek, J.R., et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes 7 (2014), 453–460.
132. Mitchell, J.D., Fergestrom, N., Gage, B.F., et al. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. J Am Coll Cardiol 72 (2018), 3233–3242.
133. Estruch, R., Ros, E., Salas-Salvadó, J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med, 378, 2018, e34.
134. Kim, H., Caulfield, L.E., Rebholz, C.M., Healthy plant-based diets are associated with lower risk of all-cause mortality in US adults. J Nutr 148 (2018), 624–631.
135. Reedy, J., Krebs-Smith, S.M., Miller, P.E., et al. Higher diet quality is associated with decreased risk of all-cause cardiovascular disease and cancer mortality among older adults. J Nutr 144 (2014), 881–889.
136. Satija, A., Bhupathiraju, S.N., Spiegelman, D., et al. Healthful and unhealthful plant-based diets and the risk of coronary heart disease in US adults. J Am Coll Cardiol 70 (2017), 411–422.
137. Sotos-Prieto, M., Bhupathiraju, S.N., Mattei, J., et al. Association of changes in diet quality with total and cause-specific mortality. N Engl J Med 377 (2017), 143–153.
138. Whalen, K.A., Judd, S., McCullough, M.L., et al. Paleolithic and Mediterranean diet pattern scores are inversely associated with all-cause and cause-specific mortality in adults. J Nutr 147 (2017), 612–620.
139. Bao, Y., Han, J., Hu, F.B., et al. Association of nut consumption with total and cause-specific mortality. N Engl J Med 369 (2013), 2001–2011.
140. Bernstein, A.M., Sun, Q., Hu, F.B., et al. Major dietary protein sources and risk of coronary heart disease in women. Circulation 122 (2010), 876–883.
141. Song, M., Fung, T.T., Hu, F.B., et al. Association of animal and plant protein intake with all-cause and cause-specific mortality. JAMA Intern Med 176 (2016), 1453–1463.
142. Tharrey, M., Mariotti, F., Mashchak, A., et al. Patterns of plant and animal protein intake are strongly associated with cardiovascular mortality: the Adventist Health Study-2 cohort. Int J Epidemiol 47 (2018), 1603–1612.
143. Martínez-González, M.A., Sánchez-Tainta, A., Corella, D., et al. A provegetarian food pattern and reduction in total mortality in the Prevención con Dieta Mediterránea (PREDIMED) study. Am J Clin Nutr 100:suppl 1 (2014), 320S–328S.
144. Wang, D.D., Li, Y., Chiuve, S.E., et al. Association of specific dietary fats with total and cause-specific mortality. JAMA Intern Med 176 (2016), 1134–1145.
145. Dehghan, M., Mente, A., Zhang, X., et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet 390 (2017), 2050–2062.
146. Sacks, F.M., Svetkey, L.P., Vollmer, W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344 (2001), 3–10.
147. Cook, N.R., Cutler, J.A., Obarzanek, E., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 334 (2007), 885–888.
148. Micha, R, Peñalvo, J.L., Cudhea, F., et al. Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. JAMA 317 (2017), 912–924.
149. Kiage, J.N., Merrill, P.D., Robinson, C.J., et al. Intake of trans fat and all-cause mortality in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) cohort. Am J Clin Nutr 97 (2013), 1121–1128.
150. Löfvenborg, J.E., Andersson, T., Carlsson, P.-O., et al. Sweetened beverage intake and risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Eur J Endocrinol 175 (2016), 605–614.
151. Yang, Q., Zhang, Z., Gregg, E.W., et al. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med 174 (2014), 516–524.
152. Johnson, R.K., Lichtenstein, A.H., Anderson, C.A.M., et al. Low-calorie sweetened beverages and cardiometabolic health: a science advisory from the American Heart Association. Circulation 138 (2018), e126–e140.
153. Shikany, J.M., Safford, M.M., Newby, P.K., et al. Southern dietary pattern is associated with hazard of acute coronary heart disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Circulation 132 (2015), 804–814.
154. Seidelmann, S.B., Claggett, B., Cheng, S., et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health 3 (2018), e419–e428.
155. Trichopoulou, A., Psaltopoulou, T., Orfanos, P., et al. Low-carbohydrate-high-protein diet and long-term survival in a general population cohort. Eur J Clin Nutr 61 (2007), 575–581.
156. Noto, H., Goto, A., Tsujimoto, T., et al. Low-carbohydrate diets and all-cause mortality: a systematic review and meta-analysis of observational studies. PLoS ONE, 8, 2013, e55030.
157. Brandt, E.J., Myerson, R., Perraillon, M.C., et al. Hospital admissions for myocardial infarction and stroke before and after the trans-fatty acid restrictions in New York. JAMA Cardiol 2 (2017), 627–634.
158. Micha, R., Mozaffarian, D., Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol 5 (2009), 335–344.
159. Mozaffarian, D., Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation 133 (2016), 187–225.
160. Weir, H.K., Anderson, R.N., Coleman King, S.M., et al. Heart disease and cancer deaths—trends and projections in the United States, 1969-2020. Prev Chronic Dis, 13, 2016, E157.
161. Micha, R., Wallace, S.K., Mozaffarian, D., Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation 121 (2010), 2271–2283.
162. Van Horn, L., Carson, J.A.S., Appel, L.J., et al. Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) guidelines: a scientific statement from the American Heart Association. Circulation 134 (2016), e505–e529.
163. Rimm, E.B., Appel, L.J., Chiuve, S.E., et al. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association. Circulation 138 (2018), e35–e47.
164. Dehghan, M., Mente, A., Rangarajan, S., et al. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet 392 (2018), 2288–2297.
165. Orrow, G., Kinmonth, A.-L., Sanderson, S., et al. Effectiveness of physical activity promotion based in primary care: systematic review and meta-analysis of randomised controlled trials. BMJ, 344, 2012, e1389.
166. Sanchez, A., Bully, P., Martinez, C., et al. Effectiveness of physical activity promotion interventions in primary care: a review of reviews. Prev Med 76:suppl (2015), S56–S67.
167. Ekelund, U., Steene-Johannessen, J., Brown, W.J., et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women. Lancet 388 (2016), 1302–1310.
168. Hamer, M., Chida, Y., Walking and primary prevention: a meta-analysis of prospective cohort studies. Br J Sports Med 42 (2008), 238–243.
169. Kyu, H.H., Bachman, V.F., Alexander, L.T., et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ, 354, 2016, i3857.
170. Sattelmair, J., Pertman, J., Ding, E.L., et al. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 124 (2011), 789–795.
171. Zheng, H., Orsini, N., Amin, J., et al. Quantifying the dose-response of walking in reducing coronary heart disease risk: meta-analysis. Eur J Epidemiol 24 (2009), 181–192.
172. Wahid, A., Manek, N., Nichols, M., et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc, 5, 2016, e002495.
173. Biswas, A., Oh, P.I., Faulkner, G.E., et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med 162 (2015), 123–132.
174. Chomistek, A.K., Manson, J.E., Stefanick, M.L., et al. Relationship of sedentary behavior and physical activity to incident cardiovascular disease: results from the Women's Health Initiative. J Am Coll Cardiol 61 (2013), 2346–2354.
175. Patterson, R., McNamara, E., Tainio, M., et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J Epidemiol 33 (2018), 811–829.
176. 2018 Physical Activity Guidelines Advisory Committee. 2018 Physical Activity Guidelines Advisory Committee Scientific Report, 2018, U.S. Department of Health and Human Services, Washington, DC Available at: https://health.gov/paguidelines/second-edition/report. (Accessed 3 January 2019)
177. Lee, I.-M., Shiroma, E.J., Lobelo, F., et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 380 (2012), 219–229.
178. Physical Activity Guidelines Steering Committee. 2008 Physical Activity Guidelines for Americans. Available at: https://health.gov/paguidelines/2008/. (Accessed 5 January 2019)
179. Milton, K., Macniven, R., Bauman, A., Review of the epidemiological evidence for physical activity and health from low- and middle-income countries. Glob Public Health 9 (2014), 369–381.
180. Lobelo, F., Rohm Young, D., Sallis, R., et al. Routine assessment and promotion of physical activity in healthcare settings: a scientific statement from the American Heart Association. Circulation 137 (2018), e495–e522.
181. Kraus, W.E., Bittner, V., Appel, L., et al. The National Physical Activity Plan: a call to action from the American Heart Association: a science advisory from the American Heart Association. Circulation 131 (2015), 1932–1940.
182. Diep, L., Kwagyan, J., Kurantsin-Mills, J., et al. Association of physical activity level and stroke outcomes in men and women: a meta-analysis. J Womens Health (Larchmt) 19 (2010), 1815–1822.
183. Sofi, F., Capalbo, A., Cesari, F., et al. Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil 15 (2008), 247–257.
184. Liu, C.-J., Latham, N.K., Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev, 2009, CD002759.
185. Sigal, R.J., Kenny, G.P., Boulé, N.G., et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 147 (2007), 357–369.
186. Carlson, D.J., Dieberg, G., Hess, N.C., et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis. Mayo Clin Proc 89 (2014), 327–334.
187. Goodman, J.M., Burr, J.F., Banks, L., et al. The acute risks of exercise in apparently healthy adults and relevance for prevention of cardiovascular events. Can J Cardiol 32 (2016), 523–532.
188. Thompson, P.D., Franklin, B.A., Balady, G.J., et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation 115 (2007), 2358–2368.
189. Merghani, A., Maestrini, V., Rosmini, S., et al. Prevalence of subclinical coronary artery disease in masters endurance athletes with a low atherosclerotic risk profile. Circulation 136 (2017), 126–137.
190. Piepoli, M.F., Hoes, A.W., Agewall, S., et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
191. Saint-Maurice, P.F., Troiano, R.P., Matthews, C.E., et al. Moderate-to-vigorous physical activity and all-cause mortality: do bouts matter?. J Am Heart Assoc, 7, 2018, e007678.
192. Vasankari, V., Husu, P., Vähä-Ypyä, H., et al. Association of objectively measured sedentary behaviour and physical activity with cardiovascular disease risk. Eur J Prev Cardiol 24 (2017), 1311–1318.
193. Pandey, A., Garg, S., Khunger, M., et al. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation 132 (2015), 1786–1794.
194. Young, D.R., Hivert, M.-F., Alhassan, S., et al. Sedentary behavior and cardiovascular morbidity and mortality: a science advisory from the American Heart Association. Circulation 134 (2016), e262–e279.
195. Chastin, S.F.M., De Craemer, M., De Cocker, K., et al. How does light-intensity physical activity associate with adult cardiometabolic health and mortality? Systematic review with meta-analysis of experimental and observational studies. Br J Sports Med, 2018 Apr 25 [Epub ahead of print].
196. LeBlanc, E.L., Patnode, C.D., Webber, E.M., et al. Draft evidence review for weight loss to prevent obesity-related morbidity and mortality in adults: behavioral interventions. Kaiser Permanente Research Affiliates Evidence-based Practice Center, Kaiser Permanente Center for Health Research: Portland, OR; 2018. AHRQ Publication No. 18-05239-EF-1. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review/obesity-in-adults-interventions1. (Accessed 5 January 2019)
197. Ma, C., Avenell, A., Bolland, M., et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ, 359, 2017, j4849.
198. Canoy, D., Cairns, B.J., Balkwill, A., et al. Coronary heart disease incidence in women by waist circumference within categories of body mass index. Eur J Prev Cardiol 20 (2013), 759–762.
199. Warren, T.Y., Wilcox, S., Dowda, M., et al. Independent association of waist circumference with hypertension and diabetes in African American women, South Carolina, 2007-2009. Prev Chronic Dis, 9, 2012, E105.
200. Czernichow, S., Kengne, A.-P., Stamatakis, E., et al. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies. Obes Rev 12 (2011), 680–687.
201. Flint, A.J., Rexrode, K.M., Hu, F.B., et al. Body mass index, waist circumference, and risk of coronary heart disease: a prospective study among men and women. Obes Res Clin Pract 4 (2010), e171–e181.
202. American Heart Association. Extreme Obesity, And What You Can Do. Available at: https://www.heart.org/en/healthy-living/healthy-eating/losing-weight/extreme-obesity-and-what-you-can-do. (Accessed 5 January 2019)
203. Hales, C.M., Carroll, M.D., Fryar, C.D., et al. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief, 2017, 1–8.
204. Asad, Z., Abbas, M., Javed, I., et al. Obesity is associated with incident atrial fibrillation independent of gender: a meta-analysis. J Cardiovasc Electrophysiol 29 (2018), 725–732.
205. Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63 (2014), 2985–3023.
206. Yanovski, S.Z., Yanovski, J.A., Long-term drug treatment for obesity: a systematic and clinical review. JAMA 311 (2014), 74–86.
207. Golzarand, M., Toolabi, K., Farid, R., The bariatric surgery and weight losing: a meta-analysis in the long- and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss in adults. Surg Endosc 31 (2017), 4331–4345.
208. Newman, A.B., Lee, J.S., Visser, M., et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 82 (2005), 872–878 quiz 915-6.
209. Zamboni, M., Mazzali, G., Zoico, E., et al. Health consequences of obesity in the elderly: a review of four unresolved questions. Int J Obes (Lond) 29 (2005), 1011–1029.
210. Miller, S.L., Wolfe, R.R., The danger of weight loss in the elderly. J Nutr Health Aging 12 (2008), 487–491.
211. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
212. Look AHEAD Research Group Wing, R.R., Bolin, P., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369 (2013), 145–154.
213. McTigue, K.M., Harris, R., Hemphill, B., et al. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 139 (2003), 933–949.
214. Stegenga, H., Haines, A., Jones, K., et al. Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance. BMJ, 349, 2014, g6608.
215. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363 (2004), 157–163.
216. Zhang, P., Wang, R., Gao, C., et al. Prevalence of central obesity among adults with normal BMI and its association with metabolic diseases in northeast China. PLoS ONE, 11, 2016, e0160402.
217. Sharma, S., Batsis, J.A., Coutinho, T., et al. Normal-weight central obesity and mortality risk in older adults with coronary artery disease. Mayo Clin Proc 91 (2016), 343–351.
218. Garvey, W.T., Mechanick, J.I., Brett, E.M., et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 22:suppl 3 (2016), 1–203.
219. Balkau, B., Deanfield, J.E., Després, J.-P., et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 116 (2007), 1942–1951.
220. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. 1998, National Heart, Lung, and Blood Institute, Bethesda, MD Available at: https://www.ncbi.nlm.nih.gov/books/NBK2003/. (Accessed 5 January 2019)
221. Huo, R., Du, T., Xu, Y., et al. Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis. Eur J Clin Nutr 69 (2015), 1200–1208.
222. Azadbakht, L., Fard, N.R.P., Karimi, M., et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care 34 (2011), 55–57.
223. Snowling, N.J., Hopkins, W.G., Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 29 (2006), 2518–2527.
224. Church, T.S., Blair, S.N., Cocreham, S., et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA 304 (2010), 2253–2262.
225. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 854–865.
226. Maruthur, N.M., Tseng, E., Hutfless, S., et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 164 (2016), 740–751.
227. Hong, J., Zhang, Y., Lai, S., et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36 (2013), 1304–1311.
228. Griffin, S.J., Leaver, J.K., Irving, G.J., Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 60 (2017), 1620–1629.
229. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
230. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
231. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
232. Wiviott, S.D., Raz, I., Bonaca, M.P., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
233. Hernandez, A.F., Green, J.B., Janmohamed, S., et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392 (2018), 1519–1529.
234. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
235. Benjamin, E.J., Virani, S.S., Callaway, C.W., et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation 137 (2018), e67–e492.
236. Gaede, P., Vedel, P., Larsen, N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
237. Liu, G., Li, Y., Hu, Y., et al. Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus. J Am Coll Cardiol 71 (2018), 2867–2876.
238. Rejeski, W.J., Ip, E.H., Bertoni, A.G., et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med 366 (2012), 1209–1217.
239. Burger, K.N.J., Beulens, J.W.J., van der Schouw, Y.T., et al. Dietary fiber, carbohydrate quality and quantity, and mortality risk of individuals with diabetes mellitus. PLoS ONE, 7, 2012, e43127.
240. Micha, R., Wallace, S.K., Mozaffarian, D., Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation 121 (2010), 2271–2283.
241. Pan, A., Sun, Q., Bernstein, A.M., et al. Changes in red meat consumption and subsequent risk of type 2 diabetes mellitus: three cohorts of US men and women. JAMA Intern Med 173 (2013), 1328–1335.
242. Boulé, N.G., Haddad, E., Kenny, G.P., et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 286 (2001), 1218–1227.
243. Diabetes Control and Complications Trial Research Group Nathan, D.M., Genuth, S., et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
244. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 837–853.
245. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
246. Ray, K.K., Seshasai, S.R.K., Wijesuriya, S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (2009), 1765–1772.
247. Zelniker, T.A., Wiviott, S.D., Raz, I., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, 2018, 10.1016/S0140-6736(18)32590-X.
248. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 Nov 10 [E-pub ahead of print].
249. Cholesterol Treatment Trialists’ (CTT) Collaboration Baigent, C., Blackwell, L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
250. Baigent, C., Landray, M.J., Reith, C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
251. Cholesterol Treatment Trialists’ (CTT) Collaboration Herrington, W., Emberson, J., et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4 (2016), 829–839.
252. Chou, R., Dana, T., Blazina, I., et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force. Report No. 14-05206-EF-2. 2016, U.S. Agency for Healthcare Research and Quality, Rockville, MD Available at: http://www.ncbi.nlm.nih.gov/books/NBK396415. (Accessed 5 January 2019)
253. Downs, J.R., Clearfield, M., Weis, S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998), 1615–1622.
254. Ridker, P.M., Danielson, E., Fonseca, F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
255. Taylor, F., Huffman, M.D., Macedo, A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2013, CD004816.
256. Yusuf, S., Bosch, J., Dagenais, G., et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2021–2031.
257. Silverman, M.G., Ference, B.A., Im, K., et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316 (2016), 1289–1297.
258. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004), 685–696.
259. Collins, R., Armitage, J., Parish, S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003), 2005–2016.
260. de Vries, F.M., Denig, P., Pouwels, K.B., et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 72 (2012), 2365–2373.
261. Knopp, R.H., d'Emden, M., Smilde, J.G., et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006), 1478–1485.
262. Mulnier, H.E., Seaman, H.E., Raleigh, V.S., et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia 51 (2008), 1639–1645.
263. Rana, J.S., Liu, J.Y., Moffet, H.H., et al. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med 31 (2016), 387–393.
264. Sever, P.S., Poulter, N.R., Dahlöf, B., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 (2005), 1151–1157.
265. Soedamah-Muthu, S.S., Fuller, J.H., Mulnier, H.E., et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 29 (2006), 798–804.
266. Wong, N.D., Glovaci, D., Wong, K., et al. Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res 9 (2012), 146–152.
267. Besseling, J., Hovingh, G.K., Huijgen, R., et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol 68 (2016), 252–260.
268. Khera, A.V., Won, H.-H., Peloso, G.M., et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 67 (2016), 2578–2589.
269. Nanchen, D., Gencer, B., Muller, O., et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation 134 (2016), 698–709.
270. Perak, A.M., Ning, H., de Ferranti, S.D., et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. Circulation 134 (2016), 9–19.
271. Shepherd, J., Cobbe, S.M., Ford, I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995), 1301–1307.
272. Versmissen, J., Oosterveer, D.M., Yazdanpanah, M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ, 337, 2008, a2423.
273. Mortensen, M.B., Fuster, V., Muntendam, P., et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol 68 (2016), 881–891.
274. Willeit, P., Kiechl, S., Kronenberg, F., et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64 (2014), 851–860.
275. Nasir, K., Bittencourt, M.S., Blaha, M.J., et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 66 (2015), 1657–1668.
276. Ridker, P.M., Mora, S., Rose, L., et al. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J 37 (2016), 1373–1379.
277. Yano, Y., O'Donnell, C.J., Kuller, L., et al. Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA Cardiol 2 (2017), 986–994.
278. Malik, S., Zhao, Y., Budoff, M., et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol 2 (2017), 1332–1340.
279. Sniderman, A.D., Tsimikas, S., Fazio, S., The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol 63 (2014), 1935–1947.
280. Sniderman, A.D., Williams, K., Contois, J.H., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 4 (2011), 337–345.
281. Budoff, M.J., Young, R., Burke, G., et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J 39 (2018), 2401–2408.
282. Cholesterol Treatment Trialists’ (CTT) Collaborators Mihaylova, B., Emberson, J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
283. Nakamura, H., Arakawa, K., Itakura, H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006), 1155–1163.
284. Vallejo-Vaz, A.J., Robertson, M., Catapano, A.L., et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation 136 (2017), 1878–1891.
285. Mora, S., Glynn, R.J., Hsia, J., et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121 (2010), 1069–1077.
286. Samarasekera, E.J., Neilson, J.M., Warren, R.B., et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 133 (2013), 2340–2346.
287. Feinstein, M.J., Nance, R.M., Drozd, D.R., et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol 2 (2017), 155–162.
288. DeFilippis, A.P., Young, R., Carrubba, C.J., et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 162 (2015), 266–275.
289. Carr, J.J., Jacobs, D.R. Jr., Terry, J.G., et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol 2 (2017), 391–399.
290. Fudim, M., Zalawadiya, S., Patel, D.K., et al. Data on coronary artery calcium score performance and cardiovascular risk reclassification across gender and ethnicities. Data Brief 6 (2016), 578–581.
291. Gupta, A., Lau, E., Varshney, R., et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. J Am Coll Cardiol Img 10 (2017), 833–842.
292. Han, D., Ó Hartaigh, B., Lee, J.H., et al. Assessment of coronary artery calcium scoring for statin treatment strategy according to ACC/AHA guidelines in asymptomatic Korean adults. Yonsei Med J 58 (2017), 82–89.
293. Hong, J.C., Blankstein, R., Shaw, L.J., et al. Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC/AHA cholesterol management guidelines: a cost-effectiveness analysis. J Am Coll Cardiol Img 10 (2017), 938–952.
294. Kavousi, M., Desai, C.S., Ayers, C., et al. Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis. JAMA 316 (2016), 2126–2134.
295. Mahabadi, A.A., Möhlenkamp, S., Lehmann, N., et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. J Am Coll Cardiol Img 10 (2017), 143–153.
296. McClelland, R.L., Jorgensen, N.W., Budoff, M., et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). J Am Coll Cardiol 66 (2015), 1643–1653.
297. Pursnani, A., Massaro, J.M., D'Agostino, R.B. Sr., et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA 314 (2015), 134–141.
298. Qureshi, W.T., Rana, J.S., Yeboah, J., et al. Risk stratification for primary prevention of coronary artery disease: roles of C-reactive protein and coronary artery calcium. Curr Cardiol Rep, 17, 2015, 110.
299. Shah, R.V., Spahillari, A., Mwasongwe, S., et al. Subclinical atherosclerosis, statin eligibility, and outcomes in African American individuals: the Jackson Heart Study. JAMA Cardiol 2 (2017), 644–652.
300. Waheed, S., Pollack, S., Roth, M., et al. Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study. Atherosclerosis 255 (2016), 193–199.
301. Yeboah, J., Polonsky, T.S., Young, R., et al. Utility of nontraditional risk markers in individuals ineligible for statin therapy according to the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. Circulation 132 (2015), 916–922.
302. Yeboah, J., Young, R., McClelland, R.L., et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol 67 (2016), 139–147.
303. Krumholz, H.M., Treatment of cholesterol in 2017. JAMA 318 (2017), 417–418.
304. Martin, S.S., Sperling, L.S., Blaha, M.J., et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines. J Am Coll Cardiol 65 (2015), 1361–1368.
305. Cohen, R., Budoff, M., McClelland, R.L., et al. Significance of a positive family history for coronary heart disease in patients with a zero coronary artery calcium score (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol 114 (2014), 1210–1214.
306. Pandya, A., Sy, S., Cho, S., et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 314 (2015), 142–150.
307. Singh, A., Collins, B.L., Gupta, A., et al. Cardiovascular risk and statin eligibility of young adults after an MI: Partners YOUNG-MI Registry. J Am Coll Cardiol 71 (2018), 292–302.
308. Huo, X., Gao, L., Guo, L., et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol 4 (2016), 115–124.
309. Svensson, M.K., Cederholm, J., Eliasson, B., et al. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. Diab Vasc Dis Res 10 (2013), 520–529.
310. Guo, V.Y., Cao, B., Wu, X., et al. Prospective association between diabetic retinopathy and cardiovascular disease—a systematic review and meta-analysis of cohort studies. J Stroke Cerebrovasc Dis 25 (2016), 1688–1695.
311. Brownrigg, J.R.W., de Lusignan, S., McGovern, A., et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart 100 (2014), 1837–1843.
312. Ogren, M., Hedblad, B., Engström, G., et al. Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study “Men born in 1914” from Malmö, Sweden. Eur J Vasc Endovasc Surg 29 (2005), 182–189.
313. Pang, X.-H., Han, J., Ye, W.-L., et al. Lower extremity peripheral arterial disease is an independent predictor of coronary heart disease and stroke risks in patients with type 2 diabetes mellitus in China. Int J Endocrinol, 2017, 2017, 9620513.
314. Whelton, P.K., Carey, R.M., Aronow, W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71 (2018), e127–e248.
315. Neter, J.E., Stam, B.E., Kok, F.J., et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42 (2003), 878–884.
316. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 267 (1992), 1213–1220.
317. Whelton, P.K., Kumanyika, S.K., Cook, N.R., et al. Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. Am J Clin Nutr 65 (1997), 652S–660S.
318. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 157 (1997), 657–667.
319. Sacks, F.M., Svetkey, L.P., Vollmer, W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344 (2001), 3–10.
320. Appel, L.J., Moore, T.J., Obarzanek, E., et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336 (1997), 1117–1124.
321. Appel, L.J., Champagne, C.M., Harsha, D.W., et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 289 (2003), 2083–2093.
322. Mozaffarian, D., Fahimi, S., Singh, G.M., et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 371 (2014), 624–634.
323. He, F.J., Li, J., Macgregor, G.A., Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ, 346, 2013, f1325.
324. Whelton, P.K., Appel, L.J., Espeland, M.A., et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 279 (1998), 839–846.
325. Aburto, N.J., Ziolkovska, A., Hooper, L., et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ, 346, 2013, f1326.
326. Graudal, N.A., Hubeck-Graudal, T., Jürgens, G., Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens 25 (2012), 1–15.
327. Whelton, P.K., He, J., Cutler, J.A., et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 277 (1997), 1624–1632.
328. Aburto, N.J., Hanson, S., Gutierrez, H., et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ, 346, 2013, f1378.
329. Geleijnse, J.M., Kok, F.J., Grobbee, D.E., Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens 17 (2003), 471–480.
330. World Health Association. Guideline: Potassium Intake for Adults and Children. 2012, World Health Organization, Department of Nutrition for Health and Development, Geneva, Switzerland.
331. Whelton, P.K., He, J., Health effects of sodium and potassium in humans. Curr Opin Lipidol 25 (2014), 75–79.
332. Cornelissen, V.A., Smart, N.A., Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc, 2, 2013, e004473.
333. Whelton, S.P., Chin, A., Xin, X., et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 136 (2002), 493–503.
334. Carlson, D.J., Dieberg, G., Hess, N.C., et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis. Mayo Clin Proc 89 (2014), 327–334.
335. García-Hermoso, A., Saavedra, J.M., Escalante, Y., Effects of exercise on resting blood pressure in obese children: a meta-analysis of randomized controlled trials. Obes Rev 14 (2013), 919–928.
336. Rossi, A.M., Moullec, G., Lavoie, K.L., et al. The evolution of a Canadian Hypertension Education Program recommendation: the impact of resistance training on resting blood pressure in adults as an example. Can J Cardiol 29 (2013), 622–627.
337. Roerecke, M., Kaczorowski, J., Tobe, S.W., et al. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2 (2017), e108–e120.
338. Xin, X., He, J., Frontini, M.G., et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 38 (2001), 1112–1117.
339. Stewart, S.H., Latham, P.K., Miller, P.M., et al. Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction 103 (2008), 1622–1628.
340. Dickinson, H.O., Mason, J.M., Nicolson, D.J., et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24 (2006), 215–233.
341. Wallace, P., Cutler, S., Haines, A., Randomised controlled trial of general practitioner intervention in patients with excessive alcohol consumption. BMJ 297 (1988), 663–668.
342. Lang, T., Nicaud, V., Darné, B., et al. Improving hypertension control among excessive alcohol drinkers: a randomised controlled trial in France. The WALPA Group. J Epidemiol Community Health 49 (1995), 610–616.
343. Law, M.R., Morris, J.K., Wald, N.J., Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
344. Ettehad, D., Emdin, C.A., Kiran, A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
345. Sundström, J., Arima, H., Jackson, R., et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 162 (2015), 184–191.
346. Xie, X., Atkins, E., Lv, J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
347. SPRINT Research Group Wright, J.T. Jr., Williamson, J.D., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
348. Czernichow, S., Zanchetti, A., Turnbull, F., et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 29 (2011), 4–16.
349. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384 (2014), 591–598.
350. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels—overview and meta-analyses of randomized trials. J Hypertens 32 (2014), 2296–2304.
351. Thompson, A.M., Hu, T., Eshelbrenner, C.L., et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305 (2011), 913–922.
352. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels—updated overview and meta-analyses of randomized trials. J Hypertens 34 (2016), 613–622.
353. Verdecchia, P., Angeli, F., Gentile, G., et al. More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis. Hypertension 68 (2016), 642–653.
354. Bangalore, S., Toklu, B., Gianos, E., et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med 130 (2017), 707–719.e8.
355. Bundy, J.D., Li, C., Stuchlik, P., et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol 2 (2017), 775–781.
356. Ruggenenti, P., Perna, A., Loriga, G., et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365 (2005), 939–946.
357. Wright, J.T. Jr., Bakris, G., Greene, T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288 (2002), 2421–2431.
358. Upadhyay, A., Earley, A., Haynes, S.M., et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 154 (2011), 541–548.
359. Jafar, T.H., Stark, P.C., Schmid, C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139 (2003), 244–252.
360. Lv, J., Ehteshami, P., Sarnak, M.J., et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185 (2013), 949–957.
361. Klahr, S., Levey, A.S., Beck, G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330 (1994), 877–884.
362. Emdin, C.A., Rahimi, K., Neal, B., et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313 (2015), 603–615.
363. Arguedas, J.A., Leiva, V., Wright, J.M., Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev, 2013, CD008277.
364. Margolis, K.L., O'Connor, P.J., Morgan, T.M., et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 37 (2014), 1721–1728.
365. Bress, A.P., Bellows, B.K., King, J.B., et al. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J Med 377 (2017), 745–755.
366. Soliman, E.Z., Byington, R.P., Bigger, J.T., et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes blood pressure trial. Hypertension 66 (2015), 1123–1129.
367. ACCORD Study Group Cushman, W.C., Evans, G.W., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
368. Lewington, S., Clarke, R., Qizilbash, N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
369. Kassaï, B., Boissel, J.-P., Cucherat, M., et al. Treatment of high blood pressure and gain in event-free life expectancy. Vasc Health Risk Manag 1 (2005), 163–169.
370. van Dieren, S., Kengne, A.P., Chalmers, J., et al. Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract 98 (2012), 83–90.
371. Montgomery, A.A., Fahey, T., Ben-Shlomo, Y., et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens 21 (2003), 1753–1759.
372. Lonn, E.M., Bosch, J., López-Jaramillo, P., et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2009–2020.
373. Neaton, J.D., Grimm, R.H. Jr., Prineas, R.J., et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 270 (1993), 713–724.
374. Julius, S., Nesbitt, S.D., Egan, B.M., et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006), 1685–1697.
375. Lawes, C.M.M., Bennett, D.A., Lewington, S., et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med 2 (2002), 355–368.
376. Danaei, G., Ding, E.L., Mozaffarian, D., et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med, 6, 2009, e1000058.
377. Muntner, P., Carey, R.M., Gidding, S., et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. J Am Coll Cardiol 71 (2018), 109–118.
378. Blumenthal, J.A., Babyak, M.A., Hinderliter, A., et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med 170 (2010), 126–135.
379. Reboussin, D.M., Allen, N.B., Griswold, M.E., et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71 (2018), 2176–2198.
380. Baker, S., Priest, P., Jackson, R., Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ 320 (2000), 680–685.
381. Eddy, D.M., Adler, J., Patterson, B., et al. Individualized guidelines: the potential for increasing quality and reducing costs. Ann Intern Med 154 (2011), 627–634.
382. Karmali, K.N., Lloyd-Jones, D.M., Global risk assessment to guide blood pressure management in cardiovascular disease prevention. Hypertension 69 (2017), e2–e9.
383. Muntner, P., Whelton, P.K., Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol 69 (2017), 2446–2456.
384. Brunström, M., Carlberg, B., Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, 352, 2016, i717.
385. Appel, L.J., Wright, J.T. Jr., Greene, T., et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363 (2010), 918–929.
386. Reboldi, G., Gentile, G., Angeli, F., et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 29 (2011), 1253–1269.
387. Action to Control Cardiovascular Risk in Diabetes Study Group Gerstein, H.C., Miller, M.E., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
388. Julius, S., Kaciroti, N., Egan, B.M., et al. TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. J Am Soc Hypertens 2 (2008), 39–43.
389. Lüders, S., Schrader, J., Berger, J., et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26 (2008), 1487–1496.
390. Allen, N.B., Siddique, J., Wilkins, J.T., et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA 311 (2014), 490–497.
391. Inder, J.D., Carlson, D.J., Dieberg, G., et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit. Hypertens Res 39 (2016), 88–94.
392. Roerecke, M., Kaczorowski, J., Tobe, S.W., et al. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2 (2017), e108–e120.
393. National Institute on Alcohol Abuse and Alcoholism. What Is A Standard Drink?. Available at: https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/what-standard-drink. (Accessed 16 August 2017)
394. National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Blood Pressure With DASH—How Do I Make the DASH?. Available at: https://health.gov/dietaryguidelines/dga2005/toolkit/DASH/how_make_dash.htm. (Accessed 6 January 2019)
395. Top 10 Dash Diet Tips. Available at: http://dashdiet.org/dash-diet-tips.html. (Accessed 6 January 2019)
396. Carson, K.V., Verbiest, M.E.A., Crone, M.R., et al. Training health professionals in smoking cessation. Cochrane Database Syst Rev, 2012, CD000214.
397. Patnode, C.D., Henderson, J.T., Thompson, J.H., et al. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force. Ann Intern Med 163 (2015), 608–621.
398. Stead, L.F., Koilpillai, P., Fanshawe, T.R.1, et al. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev, 3, 2016, CD008286.
399. Pan, A., Wang, Y., Talaei, M., et al. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation 132 (2015), 1795–1804.
400. Mons, U., Müezzinler, A., Gellert, C., et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ, 350, 2015, h1551.
401. Lv, X., Sun, J., Bi, Y., et al. Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis. Int J Cardiol 199 (2015), 106–115.
402. U.S. National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. 2014, U.S. Centers for Disease Control and Prevention, Atlanta, GA Available at: http://www.ncbi.nlm.nih.gov/books/NBK179276. (Accessed 5 January 2019)
403. Teo, K.K., Ounpuu, S., Hawken, S., et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368 (2006), 647–658.
404. U.S. Department of Health and Human Services. Healthy People 2020. Washington, DC: 2010. Available at: https://www.healthypeople.gov. Accessed January 3, 2019.
405. Bhatnagar, A., Whitsel, L.P., Ribisl, K.M., et al. Electronic cigarettes: a policy statement from the American Heart Association. Circulation 130 (2014), 1418–1436.
406. Bhatnagar, A., cardiovascular perspective of the promises and perils of e-cigarettes. Circ Res 118 (2016), 1872–1875.
407. Lippi, G., Favaloro, E.J., Meschi, T., et al. E-cigarettes and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 40 (2014), 60–65.
408. Moheimani, R.S., Bhetraratana, M., Yin, F., et al. Increased cardiac sympathetic activity and oxidative stress in habitual electronic cigarette users: implications for cardiovascular risk. JAMA Cardiol 2 (2017), 278–284.
409. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline panel, staff, and consortium representatives. JAMA 283 (2000), 3244–3254.
410. Tobacco Use and Dependence Guideline Panel Treating Tobacco Use and Dependence: 2008 Update, 2008, U.S. Department of Health and Human Services, Washington, DC.
411. Pbert, L., Fletcher, K.E., Flint, A.J., et al. Smoking prevention and cessation intervention delivery by pediatric providers, as assessed with patient exit interviews. Pediatrics 118 (2006), e810–e824.
412. Wang, M., Wang, J.-W., Cao, S.-S., et al. Cigarette smoking and electronic cigarettes use: a meta-analysis. Int J Environ Res Public Health, 13, 2016, 120, 10.3390/ijerph13010120.
413. Jha, P., Ramasundarahettige, C., Landsman, V., et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 368 (2013), 341–350.
414. Barua, R.S., Rigotti, N.A., Benowitz, N.L., et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 72 (2018), 3332–3365.
415. Anthenelli, R.M., Benowitz, N.L., West, R., et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind randomised, placebo-controlled clinical trial. Lancet 387 (2016), 2507–2520.
416. Prochaska, J.J., Benowitz, N.L., The past, present, and future of nicotine addiction therapy. Annu Rev Med 67 (2016), 467–486.
417. Rigotti, N.A., Clair, C., Munafo, M.R., et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev, 2012, CD001837.
418. U.S. Preventive Services Task Force. Final Recommendation Statement: Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions1, 2017. (Accessed 5 January 2019)
419. Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Public Health Consequences of E-Cigarettes. Available at: http://nationalacademies.org/hmd/Reports/2018/public-health-consequences-of-e-cigarettes.aspx, 2018. (Accessed 5 January 2019)
420. Ahmed, A.A., Patel, K., Nyaku, M.A., et al. Risk of heart failure and death after prolonged smoking cessation: role of amount and duration of prior smoking. Circ Heart Fail 8 (2015), 694–701.
421. Khan, R.J., Stewart, C.P., Davis, S.K., et al. The risk and burden of smoking related heart disease mortality among young people in the United States. Tob Induc Dis, 13, 2015, 16.
422. NAADAC, the Association for Addiction Professionals. National Certificate in Tobacco Treatment Practice (NCTTP). Available at: https://www.naadac.org/NCTTP. (Accessed 5 January 2019)
423. Association for the Treatment of Tobacco Use and Dependence (ATTUD). Available at: http://www.attud.org. (Accessed 5 January 2019)
424. Council for Tobacco Treatment Training Programs. Accredited programs. Available at: http://ctttp.org/accredited-programs. (Accessed 30 January 2019)
425. Otsuka, R., Watanabe, H., Hirata, K., et al. Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA 286 (2001), 436–441.
426. Oono, I.P., Mackay, D.F., Pell, J.P., Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf) 33 (2011), 496–502.
427. U.S. Institute of Medicine Committee on Secondhand Smoke Exposure and Acute Coronary Events. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. 2010, National Academies Press, Washington, DC Available at: http://www.ncbi.nlm.nih.gov/books/NBK219565. (Accessed 5 January 2019)
428. U.S. Department of Health and Human Services. The health consequences of smoking–50 years of progress: A report of the Surgeon General. ed. Atlanta, GA: 2014.
429. Tobacco Control Legal Consortium, Public Health Law Center. HUD's rule to restrict smoking in public housing: an overview. Available at: https://publichealthlawcenter.org/sites/default/files/resources/HUD-Final-Rule-Smoke-Free-Public-Housing-2016.pdf, 2017. (Accessed 5 January 2019)
430. Guirguis-Blake, J.M., Evans, C.V., Senger, C.A., et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 164 (2016), 804–813.
431. Whitlock, E.P., Burda, B.U., Williams, S.B., et al. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 164 (2016), 826–835.
432. Lotrionte, M., Biasucci, L.M., Peruzzi, M., et al. Which aspirin dose and preparation is best for the long-term prevention of cardiovascular disease and cancer? Evidence from a systematic review and network meta-analysis. Prog Cardiovasc Dis 58 (2016), 495–504.
433. Raju, N., Sobieraj-Teague, M., Bosch, J., et al. Updated meta-analysis of aspirin in primary prevention of cardiovascular disease. Am J Med 129 (2016), e35–e36.
434. Ogawa, H., Nakayama, M., Morimoto, T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008), 2134–2141.
435. Belch, J., MacCuish, A., Campbell, I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337, 2008, a1840.
436. Fowkes, F.G.R., Price, J.F., Stewart, M.C.W., et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303 (2010), 841–848.
437. Ikeda, Y., Shimada, K., Teramoto, T., et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312 (2014), 2510–2520.
438. McNeil, J.J., Wolfe, R., Woods, R.L., et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 379 (2018), 1509–1518.
439. García Rodríguez, L.A., Martín-Pérez, M., Hennekens, C.H., et al. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS ONE, 11, 2016, e0160046.
440. Capodanno, D., Angiolillo, D.J., Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation 134 (2016), 1579–1594.
441. Antithrombotic Trialists’ (ATT) Collaboration Baigent, C., Blackwell, L., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
442. Piepoli, M.F., Hoes, A.W., Agewall, S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
443. Pearson, T.A., Blair, S.N., Daniels, S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106 (2002), 388–391.
444. Bibbins-Domingo, K., U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164 (2016), 836–845.
445. ASCEND Study Collaborative Group Bowman, L., Mafham, M., et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379 (2018), 1529–1539.
446. Gaziano, J.M., Brotons, C., Coppolecchia, R., et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392 (2018), 1036–1046.
447. Pignone, M., Alberts, M.J., Colwell, J.A., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 121 (2010), 2694–2701.
448. Halvorsen, S., Andreotti, F., ten Berg, J.M., et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 64 (2014), 319–327.
449. Mora, S., Manson, J.E., Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment. JAMA Intern Med 176 (2016), 1195–1204.
450. Miedema, M.D., Duprez, D.A., Misialek, J.R., et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes 7 (2014), 453–460.
451. Rothwell, P.M., Cook, N.R., Gaziano, J.M., et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 392 (2018), 387–399.
452. Ridker, P.M., Should aspirin be used for primary prevention in the post-statin Era?. N Engl J Med 379 (2018), 1572–1574.
453. Weintraub, W.S., Daniels, S.R., Burke, L.E., et al. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation 124 (2011), 967–990.
454. Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
455. Bress, A.P., Bellows, B.K., King, J.B., et al. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J Med 377 (2017), 745–755.
456. Moran, A.E., Odden, M.C., Thanataveerat, A., et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med 372 (2015), 447–455.
457. Park, C., Wang, G., Durthaler, J.M., et al. Cost-effectiveness analyses of antihypertensive medicines: a systematic review. Am J Prev Med 53 (2017), S131–S142.
458. Richman, I.B., Fairley, M., Jørgensen, M.E., et al. Cost-effectiveness of intensive blood pressure management. JAMA Cardiol 1 (2016), 872–879.
459. Heller, D.J., Coxson, P.G., Penko, J., et al. Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke. Circulation 136 (2017), 1087–1098.
460. Odden, M.C., Pletcher, M.J., Coxson, P.G., et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med 162 (2015), 533–541.
461. Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes 2 (2009), 65–72.
462. Lehr, A.L., Driver, S.L., Stone, N.J., The ABCDs of lifestyle counseling. JAMA Cardiol 1 (2016), 505–506.
463. Patnode, C.D., Evans, C.V., Senger, C.A., et al. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 318 (2017), 175–193.
464. LeBlanc, E.S., Patnode, C.D., Webber, E.M., et al. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 320 (2018), 1172–1191.
465. Selph, S., Dana, T., Bougatsos, C., et al. Screening for abnormal glucose and type 2 diabetes mellitus: a systematic review to update the 2008 U.S. Preventive Services Task Force Recommendation. Report No. 13-05190-EF-1. 2015, U.S. Agency for Healthcare Research and Quality, Rockville, MD Available at: http://www.ncbi.nlm.nih.gov/books/NBK293871. (Accessed 5 January 2019)
466. Patnode, C.D., Henderson, J.T., Thompson, J.H., et al. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force. Ann Intern Med 163 (2015), 608–621.
467. Guirguis-Blake, J.M., Evans, C.V., Senger, C.A., et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 164 (2016), 804–813.